Effect of statins on the progression of bioprosthetic aortic valve degeneration

Antonini‐Canterin, Francesco; Zuppiroli, Alfredo; Popescu, Bogdan A.; Granata, Gianluca; Cervesato, Eugenio; Piazza, Rita; Pavan, Daniela; Nicolosi, Gian Luigi

doi:10.1016/j.amjcard.2003.08.066

Cited by 70 publications

(46 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Moreover, it has been suggested that statins could slow the progression of bioprosthetic valve degeneration. 3,4 Finally, the metabolic syndrome (MS), a cluster of atherogenic, inflammatory, and atherothrombotic abnormalities linked to abdominal obesity and insulin resistance, has been reported to be an independent predictor of poor prognosis in native valve disease and of faster degeneration of implanted bioprosthetic valves. 5,6 Clinical Perspective on p 614…”

mentioning

confidence: 99%

Type 2 Diabetes Mellitus Is Associated With Faster Degeneration of Bioprosthetic Valve

et al. 2012

View full text Add to dashboard Cite

resulted in 6184 patients (mean age 71.3Ϯ5.4 years, 60.1% male) being enrolled. Of these patients, 1731 (27.9%) had type 2 DM. The propensity score-matching algorithm successfully matched 1113 patients with type 2 DM with the same number of no-DM patients. The postmatching standard differences were less than 0.1 for each of the covariates, and 64.2% of DM patients were matched. The early (30 days) mortality rate was 7.8% (nϭ87) versus 2.9% (nϭ33) in patients with or without type 2 DM (PϽ0.001), respectively. Seven-year freedom from valve deterioration was significantly lower in patients with DM (73.2% [95% confidence interval, 61.6 -85.5] versus 95.4% [95% confidence interval, 83.9 -100], PϽ0.001). In Cox regression models with robust SEs that accounted for the clustering of matched pairs, DM was the strongest predictor of structural valve degeneration (hazard ratio 2.39 [95% confidence interval 2.28 -3.52]). When we allowed for interaction between type 2 DM and other key risk factors, DM remained a significant predictor beyond any potentially associated variable. Conclusions-Patients

show abstract

mentioning

confidence: 99%

Type 2 Diabetes Mellitus Is Associated With Faster Degeneration of Bioprosthetic Valve

et al. 2012

View full text Add to dashboard Cite

show abstract

“…380 Regarding rheumatic mitral stenosis and bioprosthetic valves, small observational studies suggest a benefit of statin treatment. 381,382 Recommendations for lipid-lowering therapy in patients with HF and valvular diseases are shown in Table 28.…”

Section: Valvular Diseasementioning

confidence: 99%

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano¹,

Reiner²,

Backer³

et al. 2011

Atherosclerosis

565

189

View full text Add to dashboard Cite

“…The OR for progression of prosthetic degeneration with statin treatment was 0.13 (95% CI 0.03 to 0.58), and the mean ± SD rate of decrease of effective orifice area was 0.031±0.052 cm 2 /year for statin-treated individuals versus 0.100±0.150 cm 2 /year for nontreated individuals (P<0.001) (11). This suggests that statin treatment may slow the progression of bioprosthetic degeneration.…”

Section: Case Presentationmentioning

confidence: 66%

“…This suggests that statin treatment may slow the progression of bioprosthetic degeneration. It is interesting that this was seen despite the presence of higher cholesterol levels in statin-treated individuals (11). It is also worth noting that the same arguments have been made with regard to the pathogenesis of aortic stenosis in native valves.…”

Section: Case Presentationmentioning

confidence: 69%